Navigation Links
Simcere Pharmaceutical Group to Announce Fourth Quarter and Fiscal Year 2011 Financial Results on Wednesday, March 7, 2012
Date:2/21/2012

NANJING, China, Feb. 21, 2012 /PRNewswire-Asia/ -- Simcere Pharmaceutical Group (NYSE: SCR), a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded generic and proprietary pharmaceuticals in China, today announced that it will report its unaudited financial results for the fourth quarter and fiscal year ended December 31, 2011 on Wednesday, March 7, 2012, before the market opens in the United States. Simcere's management will host an earnings conference call on the same day at 8 a.m. ET (Wednesday, March 7 at 9 p.m. Beijing/Hong Kong time).

To access the conference call, please dial:International toll:

+65.6723.9381United States toll-free:

+1.866.519.4004United States toll:

+1.718.354.1231China Domestic toll-free:

800.819.0121 China Domestic mobile toll-free:

400.620.8038 Hong Kong toll:

+852.2475.0994Please ask to be connected to Q4 2011 Simcere Pharmaceutical Group Earnings Conference Call and provide the following passcode: 53190629.

Simcere will also broadcast a live audio webcast of the conference call. The broadcast will be available by visiting the "Investor Relations" section of the company's web site at www.simcere.com.

Following the earnings conference call, an archive of the call will be available by dialing:United States toll-free:

+1.866.214.5335United States toll:

+1.718.354.1232The passcode for replay participants is 53190629. The telephone replay also will be archived on the "Investor Relations" section of the company's website for seven days following the earnings announcement.

About Simcere Pharmaceutical GroupSimcere Pharmaceutical Group (NYSE: SCR, Simcere) is a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded and proprietary pharmaceuticals in China. Simcere concentrates its research and development efforts on the treatment of diseases with high incidence and/or mortality rates and for which there is a clear demand for more effective pharmacotherapy such as cancer, strokes, cardiovascular disease, infectious diseases and pain. For more information about Simcere Pharmaceutical Group, please visit www.simcere.com.

Investor and Media Contacts: Email: ir@simcere.com In Nanjing:In the United States:Yehong Zhang

Cindy ZhengPresident

Brunswick GroupSimcere Pharmaceutical Group

Tel: 1-212-333-3810Tel: 86-25-8556-6666 ext. 8811In Beijing:In Hong Kong:Yue Yu

Joseph Lo Chi-LunBrunswick Group

Brunswick GroupTel: 86-10-5960-8600

Tel: 852-3512-5000
'/>"/>

SOURCE Simcere Pharmaceutical Group
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Apexigen Announces the Filing by its Partner, Simcere Pharmaceutical Group, of First IND
2. Simcere Announces 105 Drugs Included in Chinas National Drug Reimbursement List
3. Forty-two of Simceres Generic Drugs Enter Chinas Essential Drug List
4. Simcere Pharmaceutical Group Notice of Annual General Meeting
5. Simcere Pharmaceutical Group Announces Agreement to Acquire 37.5% Stake in Jiangsu Yanshen Biological Technology Stock Co., Ltd.
6. Simcere Pharmaceutical Group Appoints Dr. Peng Wang as Chief Scientific Officer
7. Simcere Pharmaceutical Group Reports Unaudited First Quarter 2009 Results
8. Simcere Pharmaceutical Group to Announce 2009 First Quarter Earnings on Monday, May 18, 2009
9. Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2008 Results
10. Simcere Pharmaceutical Group to Announce 2008 Fourth Quarter and Full Year Earnings On Thursday, March 12, 2009
11. Simcere Pharmaceutical Group Announces Preliminary Full Year Revenue and Earnings
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... 24, 2016 Epic Sciences unveiled a ... susceptible to PARP inhibitors by targeting homologous recombination ... The new test has already been incorporated into ... cancer types. Over 230 clinical trials ... pathways, including PARP, ATM, ATR, DNA-PK and WEE-1. ...
(Date:6/24/2016)... ... 2016 , ... Researchers at the Universita Politecnica delle Marche in Ancona combed ... pleural mesothelioma. Their findings are the subject of a new article on the Surviving ... signposts in the blood, lung fluid or tissue of mesothelioma patients that can help ...
(Date:6/23/2016)... ... June 23, 2016 , ... UAS LifeSciences, one of the ... brand, UP4™ Probiotics, into Target stores nationwide. The company, which has been manufacturing ... to its list of well-respected retailers. This list includes such fine stores as ...
(Date:6/23/2016)... , June 23, 2016 /PRNewswire/ - FACIT has ... Ontario biotechnology company, Propellon Therapeutics Inc. ... and commercialization of a portfolio of first-in-class WDR5 ... targets such as WDR5 represent an exciting class ... in precision medicine for cancer patients. Substantial advances ...
Breaking Biology Technology:
(Date:4/13/2016)...  IMPOWER physicians supporting Medicaid patients in ... standard in telehealth thanks to a new partnership with ... IMPOWER patients can routinely track key health measurements, such ... and, when they opt in, share them with IMPOWER ... local retail location at no cost. By leveraging this ...
(Date:3/31/2016)... -- Genomics firm Nabsys has completed a financial  restructuring under ... M.D., who returned to the company in October 2015. ... including Chief Technology Officer, John Oliver , Ph.D., ... Vice President of Software and Informatics, Michael Kaiser ... Bready served as CEO of Nabsys from 2005-2014 and ...
(Date:3/23/2016)... , March 23, 2016 ... erhöhter Sicherheit Gesichts- und Stimmerkennung mit Passwörtern ... (NASDAQ: MESG ), ein führender ... das Unternehmen mit SpeechPro zusammenarbeitet, um erstmals ... Finanzdienstleistungsbranche, wird die Möglichkeit angeboten, im Rahmen ...
Breaking Biology News(10 mins):